Carboplatin/Cisplatin + Etoposide + Benmelstobart Sequential Benmelstobart Combined With Anlotinib Versus Carboplatin/Cisplatin + Etoposide + Tislelizumab Sequential Tislelizumab in the Treatment of Extensive Stage Small Cell Lung Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

134

Participants

Timeline

Start Date

April 7, 2025

Primary Completion Date

October 31, 2026

Study Completion Date

April 30, 2027

Conditions
Extensive Stage Small Cell Lung Cancer
Interventions
DRUG

Carboplatin for injection/cisplatin for injection + etoposide injection + benmelstobart injection + Anlotinib hydrochloride capsule

Carboplatin for injection inhibits DNA synthesis, thereby preventing cancer cell division and reproduction/Cisplatin for injection binds to DNA, interfering with DNA replication and transcription processes, Thus inhibiting tumor cell proliferation/etoposide injection interferes with the division process of cancer cells to inhibit their growth and spread/Bemosubebezumab injection is a humanized recombinant anti-Programmed cell death ligand 1 (PD-L1) monoclonal antibody/Anlotinib hydrochloride capsule is a tyrosine kinase inhibitor.

DRUG

Carboplatin for injection/Cisplatin for injection + etoposide injection + Tislelizumab injection

Carboplatin for injection inhibits DNA synthesis and thus prevents the division and reproduction of cancer cells/Cisplatin for injection binds to DNA and interferes with the DNA replication and transcription process, thereby inhibiting the proliferation of tumor cells/etoposide injection interferes with the division process of cancer cells to inhibit their growth and spread/Tislelizumab injection is a humanized recombinant anti-PD-1 monoclonal antibody.

Trial Locations (28)

30000

NOT_YET_RECRUITING

Shanxi Cancer hospital, Taiyuan

100000

RECRUITING

Cancer Hospital Chinese Academy of Medical Sciences, Beijing

100044

NOT_YET_RECRUITING

Peking University People´s Hospital, Beijing

100142

NOT_YET_RECRUITING

Beijing Cancer Hospital, Beijing

110000

NOT_YET_RECRUITING

Liaoning Cancer Hospital & Institute, Shenyang

NOT_YET_RECRUITING

The First Affiliated Hospital of China Medical University, Shenyang

150000

NOT_YET_RECRUITING

The First Affiliated Hospital of Harbin Medical University, Harbin

210009

NOT_YET_RECRUITING

Jiangsu Cancer Hospital, Nanjing

243000

NOT_YET_RECRUITING

Maanshan People's Hospital, Maanshan

250000

RECRUITING

The First Affiliated Hospital of Shandong First Medical University, Jinnan

276003

NOT_YET_RECRUITING

Linyi City People's Hospital, Linyi

315000

NOT_YET_RECRUITING

Ningbo Medical Center Lihuili Hospital, Ningbo

315010

NOT_YET_RECRUITING

Ningbo No.2 Hospital, Ningbo

317000

NOT_YET_RECRUITING

Taizhou Hospital of Zhejiang Province, Taizhou

362001

NOT_YET_RECRUITING

Fujian Medical University 2nd Affiliated Hospital, Quanzhou

410011

NOT_YET_RECRUITING

The Second Xiangya Hospital of Central South University, Changsha

430000

NOT_YET_RECRUITING

Huazhong University of Science and Technology Tongji Medical College of Huazhong University of Science and Technology, Wuhan

450003

NOT_YET_RECRUITING

Henan Provincial People'S Hospital, Zhengzhou

457000

NOT_YET_RECRUITING

Henan Cancer Hospital Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou

510000

NOT_YET_RECRUITING

Cancer Hospital of Shantou University Medical College, Shantou

510515

NOT_YET_RECRUITING

Nanfang Hospital, Guangzhou

522031

NOT_YET_RECRUITING

Dongyang Municipal People's Hospital, Dongyang

610042

NOT_YET_RECRUITING

Sichuan cancer hospital, Chengdu

710000

NOT_YET_RECRUITING

The Second Affiliated Hospital Of Xi'an Jiaotong University, Xi'an

730030

NOT_YET_RECRUITING

The Second Hospitai. & Clinicae Medical School . Lanzhou University, Lanzhou

05000

NOT_YET_RECRUITING

The fourth hospital of hebei medical university, Shijiazhuang

063001

NOT_YET_RECRUITING

Tangshan People's Hospital, Tangshan

014000

NOT_YET_RECRUITING

Baotou Cancer Hospital, Baotou

All Listed Sponsors
lead

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

INDUSTRY